ANTX
AN2 Therapeutics, Inc.
$3.91
+1.56%
$138.7M
No data for this timeframe.
Vol
Market Cap$138.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders6 funds
Inst. Value$2.5M
Inst. Activity1 buys / 2 sells
Insider Activity0B / 2S
Insider Net $-$1.5K
Reddit Sentiment43° Neutral
SEC Reports4
Recent Activity
Jun 4, 2026
SEC
AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. A 28
8-K — Impact 7/10
May 29, 2026
Insider
Williams Sarah Joanne sold 265 shares
Principal Accounting Officer @ $4.43 ($1.2K)
May 13, 2026
earnings_calendar
ANTX Q1 2026 Earnings Scheduled — 2026-05-13
Apr 22, 2026
SEC
AN2 Therapeutics is holding its annual shareholder meeting to elect three Class I directors and ratify the appointment o
DEFA14A — Impact 3/10
Apr 21, 2026
SEC
AN2 Therapeutics' shelf registration on Form S-3 has become effective, allowing the company to raise up to $300 million
EFFECT — Impact 4/10
Apr 10, 2026
Insider
Martin Patricia A. sold 1,192 shares
Director @ $0.00 ($0.00)
Apr 10, 2026
Insider
Marks Gilbert Lynn sold 3,775 shares
Director @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
238,347 shares ($252.6K)
Price Targets
$9.00
+130.2% upside
Strong Buy
Current $3.91
Low $9.00
Median $9.00
High $9.00
1 analysts
$9.00
$9.00
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Leerink Partners | UPGRADE | Market Perform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 | $-0.23 — $-0.23 | -10% YoY | 1 |
| Next Q | $-0.24 ▼ -9.1% | $-0.24 — $-0.24 | 23% YoY | 1 |
| Current FY | $-0.96 ▼ -5.5% | $-0.96 — $-0.96 | 17% YoY | 1 |
| Next FY | $-1.04 ▼ -30.0% | $-1.04 — $-1.04 | -8% YoY | 1 |
Latest Reports
BULLISH
8-K
7/10
AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic Chagas disease. A 28
Jun 4, 2026
NEUTRAL
DEFA14A
3/10
AN2 Therapeutics is holding its annual shareholder meeting to elect three Class I directors and ratify the appointment o
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.2M | — |
| BANK OF AMERICA CORP | $439.3K | — |
| RENAISSANCE TECHNOLOGIES LLC | $386.0K | TRIM |
| MORGAN STANLEY | $261.9K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $203.5K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Williams Sarah | SELL | $1.2K |
| Apr 10, 2026 | Martin Patricia | A | $0.00 |
| Apr 10, 2026 | Marks Gilbert | A | $0.00 |
| Apr 10, 2026 | Aziz Kabeer | A | $0.00 |
| Mar 19, 2026 | Readnour Robin | A | $0.00 |
Reddit Sentiment
43°
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $2.5M total value (2,213,470 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, RENAISSANCE.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,080,070 | $1.2M | 48.8% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 385,312 | $439.3K | 17.4% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 338,600 | $386.0K | 15.3% | TRIM -36.4% |
| 4 | MORGAN STANLEY | 229,770 | $261.9K | 10.4% | DOUBLED +59314.3% |
| 5 | TWO SIGMA INVESTMENTS, LP | 178,518 | $203.5K | 8.1% | TRIM -30.7% |
| 6 | FMR LLC | 1,200 | $1.4K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 343,960 | 238,347 | -30.7% | $252.6K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 300 | 178,243 | +59314.3% | $188.9K | 2025-Q2 |
| UBS Group AG | TRIM | 106,021 | 62,000 | -41.5% | $65.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 579,773 | 368,708 | -36.4% | $501.4K | 2025-Q1 |
| UBS Group AG | TRIM | 170,292 | 106,021 | -37.7% | $144.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 67,994 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 423,800 | 579,773 | +36.8% | $800.1K | 2024-Q4 |
| UBS Group AG | NEW | — | 170,292 | — | $235.0K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 67,994 | — | $93.8K | 2024-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 17,461 | 303 | -98.3% | $324.00 | 2024-Q3 |
13 unique insiders with 2 transactions. Net insider value: -$1.5K ($0.00 bought, $1.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Williams Sarah Joanne | Principal Accounting Officer | SELL | 265 | $4.43 | $1.2K |
| Apr 10, 2026 | Martin Patricia A. | Director | A | 1,192 | $0.00 | $0.00 |
| Apr 10, 2026 | Marks Gilbert Lynn | Director | A | 3,775 | $0.00 | $0.00 |
| Apr 10, 2026 | Aziz Kabeer | Director | A | 3,775 | $0.00 | $0.00 |
| Mar 19, 2026 | Readnour Robin Shane | Director | A | 20,724 | $0.00 | $0.00 |
| Mar 19, 2026 | Easom Eric | Chief Executive Officer | A | 249,999 | $0.00 | $0.00 |
| Mar 19, 2026 | Readnour Robin Shane | Director | D | 20,724 | $0.00 | $0.00 |
| Mar 19, 2026 | Spigelman Melvin K | Director | A | 16,941 | $0.00 | $0.00 |
| Mar 19, 2026 | Eizen Joshua M | See Remarks | A | 92,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Zakrzewski Joseph S | Director | D | 99,999 | $0.00 | $0.00 |
| Mar 19, 2026 | Wong Stephanie | Director | D | 24,999 | $0.00 | $0.00 |
| Mar 19, 2026 | Spigelman Melvin K | Director | D | 16,941 | $0.00 | $0.00 |
| Mar 19, 2026 | Zakrzewski Joseph S | Director | A | 99,999 | $0.00 | $0.00 |
| Mar 19, 2026 | Eizen Joshua M | See Remarks | D | 92,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Wong Stephanie | Director | A | 24,999 | $0.00 | $0.00 |
| Mar 19, 2026 | FitzPatrick Margaret M | Director | A | 11,463 | $0.00 | $0.00 |
| Mar 19, 2026 | Martin Patricia A. | Director | A | 24,999 | $0.00 | $0.00 |
| Mar 19, 2026 | Aziz Kabeer | Director | A | 20,724 | $0.00 | $0.00 |
| Mar 19, 2026 | Marks Gilbert Lynn | Director | D | 10,665 | $0.00 | $0.00 |
| Mar 19, 2026 | Chanda Sanjay | Chief Development Officer | D | 66,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Chanda Sanjay | Chief Development Officer | A | 66,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Day Lucy | Chief Financial Officer | D | 73,665 | $0.00 | $0.00 |
| Mar 19, 2026 | Day Lucy | Chief Financial Officer | A | 73,665 | $0.00 | $0.00 |
| Mar 19, 2026 | Marks Gilbert Lynn | Director | A | 10,665 | $0.00 | $0.00 |
| Mar 19, 2026 | Aziz Kabeer | Director | D | 20,724 | $0.00 | $0.00 |
| Mar 19, 2026 | Martin Patricia A. | Director | D | 24,999 | $0.00 | $0.00 |
| Mar 19, 2026 | FitzPatrick Margaret M | Director | D | 11,463 | $0.00 | $0.00 |
| Mar 19, 2026 | Easom Eric | Chief Executive Officer | D | 249,999 | $0.00 | $0.00 |
| Mar 3, 2026 | Williams Sarah Joanne | Principal Accounting Officer | SELL | 327 | $1.06 | $346.62 |
| Feb 20, 2026 | Martin Patricia A. | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | Wong Stephanie | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | Spigelman Melvin K | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | Eizen Joshua M | See Remarks | A | 50,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Eizen Joshua M | See Remarks | A | 100,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Day Lucy | Chief Financial Officer | A | 38,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Day Lucy | Chief Financial Officer | A | 77,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Williams Sarah Joanne | Principal Accounting Officer | A | 48,375 | $0.00 | $0.00 |
| Feb 20, 2026 | Easom Eric | Chief Executive Officer | A | 112,250 | $0.00 | $0.00 |
| Feb 20, 2026 | Easom Eric | Chief Executive Officer | A | 224,500 | $0.00 | $0.00 |
| Feb 20, 2026 | Chanda Sanjay | Chief Development Officer | A | 38,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Chanda Sanjay | Chief Development Officer | A | 77,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Marks Gilbert Lynn | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | Readnour Robin Shane | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | Aziz Kabeer | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | FitzPatrick Margaret M | Director | A | 20,400 | $0.00 | $0.00 |
| Feb 20, 2026 | Zakrzewski Joseph S | Director | A | 20,400 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
BULLISH
8-K
7/10
AN2 Therapeutics reported positive enabling data for its oral CPSF3 inhibitor AN2-502998 in chronic
Jun 4, 2026
NEUTRAL
DEFA14A
3/10
AN2 Therapeutics is holding its annual shareholder meeting to elect three Class I directors and rati
Apr 22, 2026
NEUTRAL
EFFECT
4/10
AN2 Therapeutics' shelf registration on Form S-3 has become effective, allowing the company to raise
Apr 21, 2026
BEARISH
424B5
6/10
AN2 Therapeutics has filed a $80 million at-the-market (ATM) offering through Jefferies, allowing it
Apr 20, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.00 mean target
+130.2% upside
Strong Buy (1.00)
$9.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $3.91 |
| Target Low | $9.00 |
| Target Mean | $9.00 |
| Target Median | $9.00 |
| Target High | $9.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.23 | $-0.23 | -9.5% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.24 | $-0.24 | $-0.24 | 22.6% | -9.1% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.96 | $-0.96 | $-0.96 | 17.2% | -5.5% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-1.04 | $-1.04 | $-1.04 | -8.3% | -30.0% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $-0.230 | |
| 30d ago | $-0.230 | |
| 60d ago | $-0.230 | |
| 90d ago | $-0.230 |
1 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Leerink Partners | UPGRADE | Market Perform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
43°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
1 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 9, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 9, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 13, 2026
earnings_calendar
ANTX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
ANTX Q1 2026 Earnings Scheduled — 2026-05-11
May 1, 2026
earnings_calendar
ANTX Q1 2026 Earnings Scheduled — 2026-05-01
Mar 10, 2026
short_interest
FTD: ANTX — 188,662 shares ($1.0M) failed to deliver
Settlement: 20260310, Price: $5.25, FTD Value: $990,475.5, AN2 THERAPEUTICS INC COM